Entering text into the input field will update the search result below

Bayer on go with clinical development of Compugen-discovered therapeutic antibody

Jul. 02, 2018 7:30 AM ETCompugen Ltd. (CGEN) StockBy: Douglas W. House, SA News Editor2 Comments
  • Compugen (NASDAQ:CGEN) announces that the FDA has signed off on Bayer AG's (OTCPK:BAYRY) IND for cancer candidate BAY 1905254, an immuno-oncology therapeutic antibody targeting the ILDR2 protein in solid tumors.
  • ILDR2 is an immune checkpoint discovered by Compugen (CGEN). Phase 1 development should start later this year.
  • CGEN is up 11% premarket.
  • Previously: Compugen up 10% as FDA pulls clinical hold (July 2)

Recommended For You

About CGEN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CGEN--
Compugen Ltd.